PAMU
XLRN

Pictet Asset Management (UK)’s Acceleron Pharma XLRN Stock Holding History

Pictet Asset Management (UK)’s Portfolio XLRN Stock Details XLRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$84.2M Buy
671,041
+16,154
+2% +$2.04M 0.09% 256
2021
Q1 		$88.8M Sell
654,887
-132,493
-17% -$17.1M 0.11% 230
2020
Q4 		$101M Buy
787,380
+52,772
+7% +$6.19M 0.13% 197
2020
Q3 		$82.7M Buy
+734,608
New +$73.1M 0.13% 199
2019
Q2 		– Sell
-284,624
Closed -$13.3M – 1055
2019
Q1 		$13.3M Buy
284,624
+2,609
+0.9% +$115K 0.03% 475
2018
Q4 		$12.3K Sell
282,015
-138,565
-33% -$6.92M 0.03% 464
2018
Q3 		$24.1M Sell
420,580
-75,638
-15% -$3.72M 0.05% 378
2018
Q2 		$24.1M Sell
496,218
-19,855
-4% -$723K 0.06% 360
2018
Q1 		$20.2M Buy
516,073
+24,932
+5% +$1.06M 0.05% 377
2017
Q4 		$20.8M Sell
491,141
-138,666
-22% -$5.2M 0.05% 378
2017
Q3 		$23.5M Sell
629,807
-34,338
-5% -$1.19M 0.07% 337
2017
Q2 		$16.9M Buy
664,145
+15,612
+2% +$452K 0.05% 382
2017
Q1 		$17.2M Buy
648,533
+122,884
+23% +$3.24M 0.06% 377
2016
Q4 		$13.4M Buy
525,649
+55,543
+12% +$1.76M 0.05% 391
2016
Q3 		$17M Sell
470,106
-257,321
-35% -$8.52M 0.06% 346
2016
Q2 		$24.9M Buy
727,427
+641,327
+745% +$20.9M 0.1% 259
2016
Q1 		$2.18M Hold
86,100
– – 0.01% 682
2015
Q4 		$4.2M Buy
86,100
+24,400
+40% +$878K 0.02% 592
2015
Q3 		$1.54M Buy
61,700
+4,300
+7% +$129K 0.01% 745
2015
Q2 		$1.64M Buy
57,400
+5,800
+11% +$187K 0.01% 763
2015
Q1 		$1.43M Sell
51,600
-64,604
-56% -$2.57M 0.01% 780
2014
Q4 		$4.53M Buy
116,204
+70,604
+155% +$2.46M 0.02% 601
2014
Q3 		$1.38M Buy
45,600
+7,100
+18% +$200K 0.01% 772
2014
Q2 		$1.31M Buy
+38,500
New +$1.29M 0.01% 769

Other funds holding XLRN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Pictet Asset Management (UK)'s XLRN Position: Q2 2021 in Review

Pictet Asset Management (UK) increased its Acceleron Pharma (XLRN) stake by 2.5% in Q2 2021, buying an estimated $2.04M and bringing the position to 671,041 shares worth $84.2M. The position accounts for 0.09% of the portfolio, ranked #256.

Pictet Asset Management (UK) first reported a position in XLRN in Q2 2014 and has held it in 24 quarters since. The position peaked at $101M in Q4 2020. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

  • Pictet Asset Management (UK) held 671,041 shares of Acceleron Pharma worth $84.2M as of Q2 2021.
  • Pictet Asset Management (UK) bought 16,154 Acceleron Pharma shares in Q2 2021, an estimated $2.04M.
  • Acceleron Pharma made up 0.09% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #256 holding.
  • Pictet Asset Management (UK) first reported a position in Acceleron Pharma in Q2 2014 and has held it in 24 quarters since.
  • Pictet Asset Management (UK)'s Acceleron Pharma position peaked at $101M in Q4 2020.
  • 271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.